U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438067) titled 'EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation' on Jan. 26.
Brief Summary: This exploratory clinical study focuses on the use of EBV-AST cell infusion for treating EBV-DNA viremia following allogeneic hematopoietic stem cell transplantation (Allo-HSCT). The study aims to determine the maximum tolerated dose (MTD) or optimal biological dose (OBD) of EBV-AST cells and assess their safety, tolerability, and preliminary efficacy in treating EBV-DNA viremia. The study will involve a 3+3 dose escalation design to evaluate three different dosages of EBV-AST cell infusion. The study is expected to provide impo...